Corrigendum: PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study

Paul Little,1* FD Richard Hobbs,2 Michael Moore,1 David Mant,3 Ian Williamson,1 Cliodna McNulty,4 Gemma Lasseter,4 MY Edith Cheng,1 Geraldine Leydon,1 Lisa McDermott,1 David Turner,1 Rafael Pinedo-Villanueva,1 James Raftery,1 Paul Glasziou3 and Mark Mullee1 on behalf of the PRISM investigators

1Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK
2Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
3Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
4Public Health England, Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Gloucester, UK

*Corresponding author

Corrigendum issued October 2018
Corrigendum DOI: 10.3310/hta18060-c201810
Original DOI: 10.3310/hta18060

This report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
Corrigendum notice

PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study

Paul Little, FD Richard Hobbs, Michael Moore, David Mant, Ian Williamson, Cliodna McNulty, Gemma Lasseter, MY Edith Cheng, Geraldine Leydon, Lisa McDermott, David Turner, Rafael Pinedo-Villanueva, James Raftery, Paul Glasziou and Mark Mullee on behalf of the PRISM investigators

This paper is corrected as follows:

Page 37: The text in Chapter 4, Results, Main findings, Complications has been replaced with the following text [these data do not alter the economic modelling (which was based on the correct data), nor the inferences from the trial that the FeverPAIN score is the optimal management approach]:

There were very few complications in any trial groups: during the first trial phase there were two cases of otitis media and one case of cellulitis in the clinical score group and one case of cellulitis in the delayed antibiotic group; during the second trial phase (when using the FeverPAIN score) there were two cases of quinsy in the delayed antibiotic group and one case of otitis media in the RADT group.

Reference